We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Takeda and Metabolon Initiate Research Collaboration
News

Takeda and Metabolon Initiate Research Collaboration

Takeda and Metabolon Initiate Research Collaboration
News

Takeda and Metabolon Initiate Research Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Takeda and Metabolon Initiate Research Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Metabolon, Inc. has announced that Metabolon and Takeda Pharmaceutical Company Limited have formed a multiyear research alliance that will focus on discovering therapeutic targets and biomarkers.

Metabolon has developed a proprietary analytical platform and software for biomarker discovery using metabolomics to accelerate drug discovery and development by accurately measuring the spectrum of biochemical changes in biological samples, and mapping these changes to their corresponding metabolic pathways.

Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic.

Metabolon’s CEO John Ryals said, “We are excited about the prospect of collaborating with Takeda to accelerate its research programs. Metabolon has built a unique platform and has accumulated a vast amount of institutional knowledge in the field of metabolome analysis. We believe that integrating metabolomic profiling into Takeda’s R&D programs may lead to novel therapies and more informed decisions.

Advertisement